Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Whyte

Showing results (441-450 of 454) with videos related to

Pageof 46
Sort By:
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
BMJ Open Sport & Exercise Medicine|June 24, 2024
Establishment of clinical exercise physiology as a regulated healthcare profession in the UK: a progress reportHelen Jones, Anthony Crozier, Keith George, et al.
Bone|April 25, 2017
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRASMichael P Whyte, Malachi Griffith, Lee Trani, et al.
Human Mutation|February 24, 2011
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfectaKatarina Lindahl, Aileen M Barnes, Nadja Fratzl-Zelman, et al.
Molecular Genetics and Metabolism|December 26, 2001
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementiaM J Kovach, B Waggoner, S M Leal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 26, 2010
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled studyL M Ward, F Rauch, M P Whyte, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Pageof 46

Showing results (441-450 of 454) with videos related to

Sort By:
Pageof 46
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
BMJ Open Sport & Exercise Medicine|June 24, 2024
Establishment of clinical exercise physiology as a regulated healthcare profession in the UK: a progress reportHelen Jones, Anthony Crozier, Keith George, et al.
Bone|April 25, 2017
Melorheostosis: Exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRASMichael P Whyte, Malachi Griffith, Lee Trani, et al.
Human Mutation|February 24, 2011
COL1 C-propeptide cleavage site mutations cause high bone mass osteogenesis imperfectaKatarina Lindahl, Aileen M Barnes, Nadja Fratzl-Zelman, et al.
Molecular Genetics and Metabolism|December 26, 2001
Clinical delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementiaM J Kovach, B Waggoner, S M Leal, et al.
The Journal of Clinical Endocrinology and Metabolism|November 26, 2010
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled studyL M Ward, F Rauch, M P Whyte, et al.
JBMR Plus|May 1, 2024
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension periodLeanne M Ward, Wolfgang Högler, Francis H Glorieux, et al.
The Journal of Clinical Endocrinology and Metabolism|April 21, 2023
Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose LevelErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Calcified Tissue International|January 23, 2021
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked HypophosphatemiaRaja Padidela, Michael P Whyte, Francis H Glorieux, et al.
Lancet (London, England)|May 21, 2019
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A Imel, Francis H Glorieux, Michael P Whyte, et al.
Pageof 46